William J Gradishar

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. pmc A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 14:228. 2013
  2. doi request reprint Sorafenib in locally advanced or metastatic breast cancer
    William J Gradishar
    Maggie Daley Center for Women s Cancer Care, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Expert Opin Investig Drugs 21:1177-91. 2012
  3. ncbi request reprint Adjuvant endocrine therapy for early breast cancer: the story so far
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Invest 120:433-42. 2010
  4. doi request reprint Adjuvant endocrine therapy for early breast cancer: the story so far
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Invest 28:433-42. 2010
  5. doi request reprint Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival
    William J Gradishar
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Breast Cancer 12:313-21. 2012
  6. doi request reprint Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer
    William J Gradishar
    Northwestern University, Breast Oncology, Division of Hematology Oncology, Department of Medicine, Chicago, IL 60611, USA
    J Clin Oncol 27:3611-9. 2009
  7. ncbi request reprint Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women
    William J Gradishar
    Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Ill 60611, USA
    Oncology 69:1-9. 2005
  8. ncbi request reprint Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
  9. ncbi request reprint Controversies in the therapy of early stage breast cancer
    Mary Cianfrocca
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Oncologist 10:766-79. 2005
  10. ncbi request reprint Albumin-bound paclitaxel: a next-generation taxane
    William J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Opin Pharmacother 7:1041-53. 2006

Collaborators

Detail Information

Publications41

  1. pmc A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 14:228. 2013
    ..Here we describe RESILIENCE - a multinational, double-blind, randomized, placebo-controlled, phase 3 trial - assessing the addition of sorafenib to first- or second-line capecitabine in advanced HER2-negative breast cancer...
  2. doi request reprint Sorafenib in locally advanced or metastatic breast cancer
    William J Gradishar
    Maggie Daley Center for Women s Cancer Care, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Expert Opin Investig Drugs 21:1177-91. 2012
    ..Sorafenib is being developed in a number of solid tumors, including breast cancer (BC)...
  3. ncbi request reprint Adjuvant endocrine therapy for early breast cancer: the story so far
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Invest 120:433-42. 2010
    ..Recent data from major clinical trials are beginning to bear out this contention...
  4. doi request reprint Adjuvant endocrine therapy for early breast cancer: the story so far
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Invest 28:433-42. 2010
    ..Recent data from major clinical trials are beginning to bear out this contention...
  5. doi request reprint Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival
    William J Gradishar
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Breast Cancer 12:313-21. 2012
    ..A randomized phase II study in first-line MBC demonstrated superior efficacy and safety of weekly nab-paclitaxel compared with docetaxel. Final survival analyses and updated safety results are reported...
  6. doi request reprint Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer
    William J Gradishar
    Northwestern University, Breast Oncology, Division of Hematology Oncology, Department of Medicine, Chicago, IL 60611, USA
    J Clin Oncol 27:3611-9. 2009
    ..This phase II study examined the antitumor activity and safety of weekly and every 3 week (q3w) nab-paclitaxel compared with docetaxel as first-line treatment in patients with MBC...
  7. ncbi request reprint Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women
    William J Gradishar
    Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Ill 60611, USA
    Oncology 69:1-9. 2005
    ..Further data on the long-term safety of AIs other than anastrozole are therefore required to allow overall risk:benefit assessments on these agents to be made...
  8. ncbi request reprint Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  9. ncbi request reprint Controversies in the therapy of early stage breast cancer
    Mary Cianfrocca
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Oncologist 10:766-79. 2005
    ..There remain, however, many controversies in the primary systemic therapy of breast cancer, which are discussed in this review...
  10. ncbi request reprint Albumin-bound paclitaxel: a next-generation taxane
    William J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Opin Pharmacother 7:1041-53. 2006
    ..Taken together, these studies have demonstrated that nab technology has increased the therapeutic index of paclitaxel compared with the conventional, solvent-based formulation...
  11. ncbi request reprint Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study
    William J Gradishar
    Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:2321-7. 2004
    ..The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC)...
  12. doi request reprint A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
    William J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Eur J Cancer 49:312-22. 2013
    ....
  13. ncbi request reprint Adjuvant systemic therapy of early stage breast cancer
    William J Gradishar
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 4:141-50. 2003
    ..Long-term follow-up of patients is necessary to determine the effects of chronic aromatase inhibitor treatment on bone density, cognitive function, and other endpoints...
  14. ncbi request reprint Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer
    Mary Cianfrocca
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Natl Compr Canc Netw 5:673-5. 2007
    ..This article defends the position that combination chemotherapy is the optimal approach for patients with MBC...
  15. ncbi request reprint Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer
    Lisa E Sokolowicz
    Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Clin Breast Cancer 5:S24-30. 2004
    ..Finally, we will discuss the implications of the use of nonselective AIs in the adjuvant setting for the patient who develops recurrent metastatic disease...
  16. ncbi request reprint alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer
    Olga Ivanov
    Department of Surgery, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
    Breast Cancer Res Treat 111:411-7. 2008
    ..We examined whether alphaB-crystallin expression in breast cancer was associated with a poor response to neoadjuvant (preoperative) chemotherapy...
  17. ncbi request reprint Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    William J Gradishar
    Northwestern University, Breast Oncology, Division of Hematology Oncology, Department of Medicine, Chicago, IL 60611, USA
    J Clin Oncol 23:7794-803. 2005
    ..This phase III study was performed to confirm preclinical studies demonstrating superior efficacy and reduced toxicity of ABI-007 compared with standard paclitaxel...
  18. ncbi request reprint Current and future perspectives on fulvestrant
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center and NorthWestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
    Clin Breast Cancer 6:S23-9. 2005
    ..Although fulvestrant is undergoing robust clinical development as a treatment for breast cancer, investigation of this agent in other types of solid tumors has only just begun...
  19. ncbi request reprint The evolving role of endocrine therapy for early stage breast cancer
    Jennifer B Manders
    Department of Surgery, Division of Surgical Oncology, Feinberg School of Medicine, Northwestern University, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Breast Cancer 12:62-72. 2005
  20. ncbi request reprint Albumin-bound nanoparticle paclitaxel
    William J Gradishar
    Lynn Sage Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Clin Adv Hematol Oncol 3:348-9. 2005
  21. ncbi request reprint Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Breast Cancer 4:S26-33. 2003
    ..In this article, we are attempting to provide an overview of current use of doxorubicin and epirubicin in breast cancer..
  22. ncbi request reprint Progress in systemic adjuvant therapy of early-stage breast cancer
    William J Gradishar
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Int J Clin Oncol 8:239-47. 2003
    ..It is hoped that, in the next few years, the results of ongoing clinical trials now underway will lead to further improvements in the outcome of patients with early-stage breast cancer...
  23. ncbi request reprint Advances in endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Cancer Chemother Biol Response Modif 21:211-22. 2003
  24. doi request reprint Case records of the Massachusetts General Hospital. Case 30-2008. A 47-year-old woman with a mass in the breast and a solitary lesion in the spine
    William J Gradishar
    Department of Medicine, Northwestern University, and the Feinberg School of Medicine, Chicago, USA
    N Engl J Med 359:1382-91. 2008
  25. ncbi request reprint Clinical value of fulvestrant in breast cancer
    William J Gradishar
    Robert H Lurie Comprehensive Cancer Center and NorthWestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
    Clin Breast Cancer 6:S4. 2005
  26. ncbi request reprint Adjuvant therapy of breast cancer
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois 60611, USA
    Cancer Invest 23:548-60. 2005
    ....
  27. ncbi request reprint Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research
    Lisa E Sokolowicz
    Division of Hematology Oncology, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Oncol Rep 7:31-7. 2005
    ..Finally, we review data related to the incorporation of ovarian ablation into the treatment of early breast cancer in premenopausal women...
  28. doi request reprint The application of Oncotype DX in early-stage lymph-node-positive disease
    Sarika Jain
    Division of Hematology Oncology, Department of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
    Curr Oncol Rep 16:360. 2014
    ....
  29. ncbi request reprint Role of capecitabine (Xeloda) in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 3:137-44. 2003
    ..This review will place the available data on the use of capecitabine in metastatic breast cancer as a single agent or as part of a combination regime in context...
  30. ncbi request reprint Tamoxifen--what next?
    William J Gradishar
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, Illinois 60611, USA
    Oncologist 9:378-84. 2004
    ....
  31. ncbi request reprint The future of breast cancer: the role of prognostic factors
    William J Gradishar
    Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL, USA
    Breast Cancer Res Treat 89:S17-26. 2005
    ..Further research in breast cancer should further optimize the treatment patients receive ensuring that patients not only live longer but also have quality survival...
  32. ncbi request reprint The evolving role of endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 850, Chicago, IL 60611 2927, USA
    Cancer Chemother Biol Response Modif 20:227-38. 2002
  33. ncbi request reprint Gene expression in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 7:123-8. 2006
    ..Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many patients from receiving unnecessary toxic therapy...
  34. doi request reprint The place for eribulin in the treatment of metastatic breast cancer
    William J Gradishar
    Maggie Daley Center for Women s Cancer Care, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Oncol Rep 13:11-6. 2011
    ..This review will discuss eribulin, with focus on the potential it has to address the specific treatment needs of patients with MBC who are refractory to conventional chemotherapies...
  35. pmc Barriers to the use of personalized medicine in breast cancer
    Christine B Weldon
    Center for Business Models in Healthcare, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    J Oncol Pract 8:e24-31. 2012
    ..Using qualitative research, we explored care delivery barriers to the use of personalized medicine for patients with breast cancer using examples of BRCA and gene expression profile testing...
  36. ncbi request reprint A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience
    Ryan H Engel
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Cancer Invest 25:733-7. 2007
    ..Further, all 12 patients progressed while receiving therapy with PS-341. This study was terminated after the first stage due to the lack of any objective response...
  37. ncbi request reprint A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy
    William J Gradishar
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Clin Breast Cancer 2:282-6. 2002
    ..The data used for this analysis are directly from the EBCTCG. Our analysis suggests that women who received 1-2 years of adjuvant tamoxifen therapy may benefit from reinitiation of tamoxifen to complete a 5-year course...
  38. doi request reprint Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer
    Hannah W Hazard
    Lynn Sage Comprehensive Breast Center, Chicago, Illinois, USA
    Cancer 113:2011-9. 2008
    ..The authors reviewed chest wall status, time to first progression (TTFP), and overall survival (OS) in this group of women...
  39. doi request reprint Breast cancer and immunology: biomarker and therapeutic developments
    Cesar A Santa-Maria
    a 1 Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Division of Oncology, 676 North St Clair, Suite 880 Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 15:1215-22. 2015
    ..This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer. ..
  40. pmc Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy
    Andrew C Gordon
    Department of Radiology and Section of Interventional Radiology, Northwestern University Feinberg School of Medicine, Chicago Department of Biomedical Engineering, Northwestern University, Evanston, Illinois
    J Vasc Interv Radiol 25:1523-32, 1532.e1-2. 2014
    ....
  41. ncbi request reprint Diagnostic and treatment considerations when newly diagnosed breast cancer coincides with pregnancy: a case report and review of literature
    Lauren Nye
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Natl Compr Canc Netw 10:145-8. 2012
    ....